Mr. Ahmad Doroudian reports

BETTERLIFE PHARMA APPOINTS CHARLES DUNCAN AS DIRECTOR AND CHAIR OF THE AUDIT COMMITTEE

Betterlife Pharma Inc. has appointed Dr. Charles Duncan, PhD, as a director and chair of the audit committee.

Dr. Duncan is a biotechnology strategist, board director and former top-ranked Wall Street biotechnology analyst with nearly 30 years of experience advising investors, management teams and boards across the biopharmaceutical industry. As managing director, head, of biotech strategy and development at Gilmartin Group, he provides strategic advisory and investor engagement services to public and private life sciences companies, leveraging expertise in corporate strategy, capital markets, business development and investor communications. He also serves on the board of directors of Vanda Pharmaceuticals.

Throughout his distinguished career, Dr. Duncan has earned a reputation for combining rigorous scientific expertise with capital markets insight to help biotechnology companies create shareholder value. Over his Wall Street career, including as managing director and senior biotechnology analyst at Cantor Fitzgerald, Piper Jaffray and JMP Securities, he initiated research coverage on more than 175 biotechnology companies, evaluated over 200 investment banking transactions and served as senior vetting analyst on approximately 25 initial public offerings. His sector expertise spans neurology, psychiatry, oncology and platform-enabled therapeutics, with particular recognition as a leading authority on neuro-innovator companies.

A consistently top-ranked analyst, Dr. Duncan has received numerous industry accolades, including ranking among the top biotechnology analysts on TipRanks, Thomson Reuters StarMine and the Financial Times for stock selection and earnings forecasting. Earlier in his career, he founded a venture-backed medical device company, led pharmaceutical development programs, and managed clinical and preclinical research.

"We are delighted to welcome Charles to our board and particularly pleased that he will serve as chair of our audit committee," said Ahmad Doroudian, chief executive officer of BetterLife. "Charles brings an exceptional combination of scientific, biotechnology, capital markets and public company experience that will be highly valuable as we advance BETR-001 and continue to build our company. His deep understanding of the biopharmaceutical investment community, combined with his experience working with management teams and boards, will provide important perspective as we execute our development strategy and position the company for long-term growth."

Doug Drysdale, executive chairman of Betterlife, commented: "Betterlife is very pleased to have Charles join our board. His nearly three decades of experience across biotechnology, capital markets and corporate strategy make him an outstanding addition to our board and an excellent choice to lead our audit committee. Charles has a rare ability to evaluate biotechnology companies from both a scientific and investment perspective, and his experience as a public company director will further strengthen our governance and oversight. We look forward to benefiting from his judgment and expertise as the company enters its next phase of development."

"I am excited to join the board of Betterlife at an important stage in its development," said Dr. Duncan. "BETR-001 represents an intriguing opportunity to address significant unmet needs in migraine and headache disorders, and I believe the company has the potential to build meaningful value through disciplined clinical development and thoughtful corporate strategy. I look forward to working closely with the board and management team, contributing my experience in biotechnology, capital markets and strategic development, and helping the company realize the full potential of its programs for patients and shareholders."

Dr. Duncan holds a PhD in pharmaceutical sciences with a concentration in neuropharmacology from the University of Colorado and has completed executive education in audit committee governance at Harvard Business School.

Pursuant to the appointment of Dr. Duncan as director and chair of the audit committee, the company has agreed to grant Dr. Duncan stock options to purchase 500,000 common shares of Betterlife, with quarterly vesting over 24 months and a 10-year term. A further 125,000 stock options, with a 10-year term and vesting over three months, will also be granted to acknowledge the strategic value of Dr. Duncan's role. Exercise prices for both stock options will be in accordance with the policies of the Canadian Securities Exchange.

About Betterlife Pharma Inc.

Betterlife Pharma is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling (investigational new drug) studies, is a non-hallucinogenic and non-controlled LSD derivative in development, and is unique in that it is unregulated and therefore can be self-administered. Betterlife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042. Betterlife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

We seek Safe Harbor.